Summit Therapeutics Inc.
SMMT
Rang in Aktien
#1662
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aktienkurs
$16.14
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$12.87B
Veränderung (1 Tag)
3.65%
Veränderung (1 Jahr)
-13.88%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategorie
Healthcare
P/S-Verhältnis für Summit Therapeutics Inc. (SMMT)
P/S-Verhältnis zum October 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Summit Therapeutics Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.00. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für Summit Therapeutics Inc. von 2004 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | 1.17K | 750.59% |
| 2021 | 137.16 | -63.90% |
| 2020 | 379.96 | 488.81% |
| 2019 | 64.53 | 79.48% |
| 2018 | 35.95 | -79.79% |
| 2017 | 177.88 | -39.71% |
| 2016 | 295.05 | 149.79% |
| 2015 | 118.12 | 47.03% |
| 2014 | 80.33 | 126.64% |
| 2013 | 35.45 | 30.78% |
| 2012 | 27.10 | -86.53% |
| 2011 | 201.22 | -85.80% |
| 2010 | 1.42K | 0.83% |
| 2009 | 1.41K | 3,348.90% |
| 2008 | 40.74 | -56.22% |
| 2007 | 93.07 | -50.79% |
| 2006 | 189.15 | -68.30% |
| 2005 | 596.76 | -98.98% |
| 2004 | 58.27K | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
